European Autoimmune Disease Diagnostics Market revenue to cross $500 Mn by 2028

Published Date: 2022-09-05

Request a sample

European Autoimmune Disease Diagnostics Market size is estimated to reach USD 500 million by 2028, according to a latest forecast report by Graphical Research.

Establishment of various healthcare organizations, coupled with implementation of government initiatives, has been supporting the industry outlook. The European Autoimmunity Standardization Initiative (EASI), for instance, has been founded for enhancing better collaborations between laboratory specialist and clinicians via antibody test standardization for autoimmune conditions. Introduction of wearable technologies, such as arm gadgets for tracking blood glucose levels among patients without the need for a finger prick test.

The urinalysis segment will register over 6% CAGR through 2028. Being one of the commonly adopted assessment methods, urinalysis is extensively used for determining if the patient is suffering from hematuria, proteinuria, and active sediment. These tests are analyzed by doctors to detect diabetic nephropathy, and other abnormalities. Newer products are aiding labs and clinicians in the estimation of disease severity and confirming a diagnosis of organ-specific immunologic diseases.

Solution providers have been ensuring improved confidence in clinical decisions, at the same time offering additional features in their latest products. Siemens Heathineers, for instance, has been providing a wide range of urine analyzers for near-patient settings to meet the high productivity demand of end users. These products not only improve risk management, but also offer enhanced accuracy and flexibility for labs, hospitals, and clinics, depending on their individual needs.

U.K. autoimmune disease diagnostics industry will surpass USD 70 million by 2028, on account of growing prevalence of type 1 diabetes, Addison’s disease, and rheumatoid arthritis is expected to accelerate investments in advanced screening techniques for autoimmune conditions. According to the figures published by a registered charity Juvenile Diabetes Research Foundation (JDRF), over 400,000 individuals are presently living with type 1 diabetes in the United Kingdom, with nearly 29,000 of these being children. The estimates also suggest that the incidence rate of the condition is rising at an alarming pace of over 4% every year.

Browse detailed statistical insights from the report, “Europe Autoimmune Disease Diagnostics Market Forecast 2028 By Product (Systemic Autoimmune Disease {Rheumatoid arthritis, Ankylosing spondylitis, Systemic Lupus Erythematosus}, Localized Autoimmune Disease), By Test Type (Antinuclear Antibody Tests, Autoantibody Tests, C-reactive Protein (CRP), Complete Blood Count (CBC), Urinalysis), Research Report, Country Outlook (Germany, UK, France, Spain, Italy, Romania, Bulgaria, Portugal, Croatia, Greece, Lithuania, Estonia, Netherlands, Latvia, Belgium, Finland, Switzerland, Poland, Slovenia, Austria, Ireland, Czechia, Norway, Cyprus, Hungary, Sweden, Denmark), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @

To address numerous concerns, healthcare practitioners are recommending autoimmune antibody screening via blood tests for ruling out diagnostic possibilities. Since several leading labs services in the U.K. have been providing features, such online booking, results via email, GP referral, and free doctor interpretation of results, more patients will opt for these tests due to their convenience.

Leading autoimmune disease diagnostics solutions providers have been offering semi-automated and automated POC urinalysis testing for providing consistent and reliable result interpretation. They are catering to the wide-ranging needs for flexibility across hospitals, medical practices, and laboratories.

European autoimmune disease diagnostics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2017 to 2028, for the following segments:

Europe Market, By Disease Type

  • Systemic Autoimmune Disease
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus (SLE)
    • Psoriasis
    • Multiple Sclerosis
    • Others
  • Localized Autoimmune Disease      
    • Inflammatory Bowel Disease
    • Type 1 Diabetes
    • Thyroid
    • Others

Europe Market, By Test Type

  • Antinuclear Antibody Tests
  • Autoantibody Tests
  • C-reactive Protein (CRP)
  • Complete Blood Count (CBC)
  • Urinalysis
  • Others

The above information has been provided for the following countries:

  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy